Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Qcare Site Services

Neither a doctor nor a teaching hospital

Research payments

$7,206,431

514 payments

Through program year 2025, Qcare Site Services is reported as receiving $7,206,431 in research payments, across 514 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,603,152 208
2024 Research $3,581,378 121
2023 Research $407,868 62
2022 Research $419,173 67
2021 Research $96,849 27
2020 Research $54,043 17
2019 Research $43,968 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $5,384,816 240 payments
  2. Novavax Inc $1,156,493 27 payments
  3. Treace Medical Concepts, Inc. $427,562 152 payments
  4. GlaxoSmithKline, LLC. $111,986 40 payments
  5. Urovant Sciences Inc $37,955 22 payments
  6. Teva Pharmaceuticals USA, Inc. $28,680 6 payments
  7. Regeneron Pharmaceuticals, Inc. $22,874 10 payments
  8. Genentech, Inc. $21,672 10 payments
  9. Myovant Sciences Inc. $12,893 6 payments
  10. Sumitomo Pharma America, Inc. $1,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $1,454,907 48 payments
  2. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $1,330,305 12 payments
  3. A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age $1,113,509 109 payments
  4. A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. $960,474 25 payments
  5. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $662,233 10 payments
  6. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $576,007 25 payments
  7. A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of a JN.1 Subvariant SARS CoV-2 rS Vaccine $196,019 2 payments
  8. A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults $174,079 18 payments
  9. Align3d $106,951 46 payments
  10. Mta3d $92,563 35 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record